The leaders of Chugai Pharmaceutical are tired of their company not getting its due. At the J.P. | The leaders of Chugai ...
Vedanta Biosciences has “significantly reduced” its headcount to channel its remaining resources to its lead live bacteria ...
Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...
Boston Scientific is capping off a busy week with a major buyout, entering a deal worth about $14.5 billion to acquire ...
Hopes were high Wednesday for a billion-dollar megadeal—the kind the J.P. Morgan Healthcare Conference is known for—but no ...
The J.P. Morgan Healthcare Conference, as well as Fierce's own JPM Week, roll into Wednesday with plenty more events, ...
Looking to usher in a more “predictable” year in 2026, Illumina is working with officials in China as it remains on the ...
The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...
Still riding the high of last year’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching ...
Charles River Laboratories has struck a $510 million deal to buy a non-human primate provider, furthering efforts to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback